{"slug":"ss-31-semaglutide","verification":{"valid":true,"entries":2,"head":"1fce20a1c80dc109bdbb51aff768f30143171fac1016b58a8626d5742593a156"},"energy":{"passes":2,"tokens_in":14111,"tokens_out":3117,"tokens_total":17228,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"1fce20a1c80dc109bdbb51aff768f30143171fac1016b58a8626d5742593a156"},"provenance":[{"ts":"2026-06-29T23:47:01.542Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Semaglutide\nSlug: ss-31-semaglutide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"},{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not becau","response":"{\n  \"slug\": \"ss-31-semaglutide\",\n  \"title\": \"SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts\",\n  \"body\": \"## What's breaking down\\n\\nDegeneration often traces to layers where repair capacity falls behind ongoing stress. One layer involves mitochondrial dysfunction: cells lose efficient energy production, accumulate oxidative damage, and trigger broader tissue decline. Another layer centers on excess body weight that increases compressive forces on weight-bearing structures like the spine and joints. Each layer can outpace natural repair mechanisms. The compounds below are discussed only in relation to these studied pathways, not as symptom masks.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial dysfunction contributes to your tissue repair shortfall, SS-31 (Elamipretide) is studied because it targets that specific layer.\\n\\n1. SS-31 binds cardiolipin in the inner mitochondrial membrane.\\n2. This interaction supports electron transport chain efficiency and limits reactive oxygen species leakage.\\n3. Better mitochondrial output may support cellular energy needs for repair processes rather than masking downstream effects.\\n\\n## Why Semaglutide might help you\\n\\nIf excess body weight adds mechanical stress that overwhelms repair in weight-sensitive tissues, Semaglutide is studied because it targets metabolic load reduction.\\n\\n1. GLP-1 receptor agonism promotes weight loss through appetite and metabolic effects.\\n2. Each pound lost can reduce lumbar compressive force by roughly four pounds during activity.\\n3. Lower mechanical load may give repair pathways more headroom by decreasing ongoing tissue stress.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not copies of the same mechanism.\\n- SS-31 (Elamipretide) → mitochondrial\\n- Semaglutide → metabolic load / body weight\\n\\nThe mitochondrial approach addresses c","tokens_in":14111,"tokens_out":3117,"cost":0,"prev":"genesis","hash":"d1d915944d219444878e227b62aa421a83d9969ff436cf040433f8b26ba12169"},{"ts":"2026-07-17T02:42:07.962Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-semaglutide","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d1d915944d219444878e227b62aa421a83d9969ff436cf040433f8b26ba12169","hash":"1fce20a1c80dc109bdbb51aff768f30143171fac1016b58a8626d5742593a156"}]}